The efficacy of oral anticoagulation (OAC) alone without antiplatelet therapy in patients with atrial fibrillation (AF) and coronary artery disease (CAD) who have undergone percutaneous coronary intervention (PCI) remains to be seen, with findings of the OAC-ALONE* trial proving inconclusive, according to a study presented at the recent TCT 2018 symposium.
Percutaneous coronary intervention (PCI) with a thin composite wire strut, durable polymer-coated stent demonstrated comparable results to that using an ultrathin cobalt-chromium strut, bioresorbable polymer-coated stent, according to results of the BIONYX* trial presented at the recent TCT symposium (TCT 2018).
The risk of hospitalization due to heart failure was almost halved in patients with secondary mitral regurgitation who underwent transcatheter mitral valve repair plus medical therapy compared with those who underwent medical therapy alone, according to findings of the COAPT* trial.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.